Perseus Proteomics, Inc. (JP:4882)
:4882
Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥145.00 - ¥432.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥2.55B
Enterprise Value¥770.82M
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.44
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth over multiple years indicates expanding market traction and product adoption. That trend provides a durable foundation for future scale: if management can convert top-line gains into improved operating leverage, the revenue base supports long-term margin recovery and profitability potential.
High Gross ProfitabilityStrong gross margins imply the core product or service has favorable unit economics, offering room to absorb SG&A and R&D while moving toward breakeven. Persistent gross profitability is a structural advantage that can enable sustainable operating leverage if operating expenses are managed.
Debt-Free Balance SheetAbsence of debt materially lowers solvency risk and interest burden, giving the company strategic flexibility. A debt-free structure supports durability through cash burn periods, enabling management to prioritize R&D or commercialization without fixed financing costs that amplify downside in prolonged losses.
Bears Say
Persistent Operating LossesLarge, recurring operating losses are a structural weakness that erodes retained earnings and investor capital. Over the medium term they limit reinvestment capacity, necessitate external funding, and keep returns negative, making it difficult to convert revenue growth and gross margins into sustainable profitability.
Consistent Negative Cash FlowPersistent negative operating and free cash flow creates ongoing dependence on external financing or equity raises. Even with slight improvement year-over-year, sustained cash burn threatens runway, increases dilution risk, and constrains the company's ability to fund commercialization or scale without dilutive capital.
Erosion Of Equity BaseA marked decline in shareholders' equity reflects accumulated losses and reduces the balance sheet buffer against shocks. Diminished equity limits strategic optionality, can raise investor concern about solvency over the medium term, and may increase cost or scarcity of future capital raising.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥145.00 and its highest was ¥432.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥2.55B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 69 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on May 14, 2026. The company reported -¥11.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.03.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 16,999,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---